Search the Newsreel

Ovid Therapeutics (NASDAQ:OVID) Raised to Hold at Wall Street Zen

Wall Street Zen has upgraded Ovid Therapeutics (NASDAQ:OVID) from a "sell" to a "hold" rating, while the broader analyst consensus remains a "Moderate Buy" with a target price of $5.71. The company recently reported a quarterly loss of $0.08 per share, outperforming expectations, and …

Mineralys Therapeutics (NASDAQ:MLYS) Cut to "Strong Sell" at Wall Street Zen

Wall Street Zen downgraded Mineralys Therapeutics (NASDAQ:MLYS) to "Strong Sell" following a significant second-quarter earnings miss, where the company lost $2.85 per share against an expected $0.55 loss. Despite this, the broader analyst consensus remains a "Moderate Buy" with a $49.33 price target. Insider …

Tenax Therapeutics (NASDAQ:TENX) Rating Lowered to Strong Sell at Wall Street Zen

Wall Street Zen downgraded Tenax Therapeutics (NASDAQ:TENX) from a "sell" to a "strong sell" rating. This comes amidst other analysts also reducing their ratings, though the broader consensus remains a "Moderate Buy" with a $14 average price target. The company, which is developing pain-management …

ADC Therapeutics (NYSE:ADCT) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded ADC Therapeutics (NYSE:ADCT) from a "sell" to a "hold" rating. The company reported a quarterly loss of $0.11 per share, beating analyst estimates, with revenue of $19.25 million also exceeding expectations. Despite mixed analyst coverage, the stock has a consensus …

Outlook Therapeutics (OTLK) Stock Looks Fully Valued While Book Value Stays Unclear

Outlook Therapeutics (OTLK) stock has declined significantly over the past five years, yet recent valuation checks do not indicate it is a clear bargain. The company's negative shareholder equity makes its Price-to-Book (P/B) ratio unreliable for valuation, and despite the recent approval of LYTENAVA …

Maplight Therapeutics (NASDAQ:MPLT) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded Maplight Therapeutics (NASDAQ:MPLT) from "strong sell" to "sell," though the stock still holds a consensus "Moderate Buy" rating with an average price target of $29.67. The company recently reported better-than-expected quarterly EPS of -$1.32, and an insider director purchased 15,620 …

Aardvark Therapeutics (NASDAQ:AARD) Raised to "Sell" at Wall Street Zen

Wall Street Zen upgraded Aardvark Therapeutics (NASDAQ:AARD) from "strong sell" to "sell," while the broader analyst consensus on MarketBeat remains a "hold" with a $16.30 price target. The clinical-stage biopharmaceutical company, specializing in treatments for autoimmune and inflammatory diseases, reported a quarterly loss of …

Pliant Therapeutics (NASDAQ:PLRX) Downgraded by Wall Street Zen to Sell

Pliant Therapeutics (NASDAQ:PLRX) has been downgraded to a "sell" rating by Wall Street Zen, a sentiment echoed by Weiss Ratings, contributing to a consensus "Reduce" rating and a $3.00 target price. The stock opened at $1.07, near its 12-month low, and recently missed quarterly …

CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen has upgraded CytomX Therapeutics (NASDAQ:CTMX) stock rating from "sell" to "hold," though the overall analyst consensus remains a "Buy" with an average price target of $11.90. The company reported a quarterly loss of $0.09 per share and revenue of $1.42 million, …

Is It Smart To Buy JK Paper Limited (NSE:JKPAPER) Before It Goes Ex-Dividend?

Maze Therapeutics president sells $445,620 in company stock By Investing.com

Harold Bernstein, President, R&D & CMO at Maze Therapeutics, Inc. (NASDAQ:MAZE), sold 16,142 shares of company stock for $445,620 on August 13, 2026. This transaction followed an exercise of stock options at a lower price and was conducted under a Rule 10b5-1 trading plan. …

Aquestive Therapeutics (NASDAQ:AQST) Lowered to "Sell" Rating by Wall Street Zen

Aquestive Therapeutics (NASDAQ:AQST) has been downgraded from a "hold" to a "sell" rating by Wall Street Zen analysts. The company reported a Q2 earnings per share miss of ($0.18) against an estimated ($0.10), although revenue of $13.82 million exceeded the $11.42 million consensus. Despite …

Wall Street Zen Upgrades Bicycle Therapeutics (NASDAQ:BCYC) to "Sell"

Behavioral Patterns of TECX and Institutional Flows

This article analyzes Avrobio Inc. (NASDAQ: TECX), indicating strong sentiment across all horizons and an exceptional 58.8:1 risk-reward setup targeting a 17.8% gain. It details three AI-generated institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, and provides a multi-timeframe signal …

CEO da United Therapeutics vende ações no valor de US$ 4,79 milhões - Investing.com Brasil

H.C. Wainwright Maintains Galectin Therapeutics(GALT.US) With Buy Rating, Maintains Target Price $11

H.C. Wainwright has reiterated its Buy rating for Galectin Therapeutics (GALT.US), maintaining a target price of $11. This indicates a continued positive outlook from the firm regarding the company's stock performance and potential.

Why Did QuantumScape Stock Sink Over 10% After-Hours Today?

Edgewise Therapeutics CMO Joanne Donovan sells $412,703 in stock

Joanne M. Donovan, CMO of Edgewise Therapeutics, sold 9,441 shares totaling $412,703 in August 2026, with a portion covering tax obligations from RSU vesting and the remainder under a Rule 10b5-1 plan. These sales followed her acquisition of shares from RSU vesting and new …

Edgewise Therapeutics CSO Alan Russell sells $258k in stock

Edgewise Therapeutics' Chief Scientific Officer, Alan J. Russell, sold 5,901 shares of company stock for $258,042, primarily to cover tax obligations from RSU vesting. Following the sale, he still holds 31,466 shares directly, along with additional RSUs and stock options. This transaction follows the …

Vistagen Therapeutics (VTGN) flags going concern risk amid Q1 loss and Nasdaq pressure

Vistagen Therapeutics reported a net loss of $13.0 million for Q1 2027, an improvement from the prior year, with revenue increasing to $1.5 million. Despite this, the company flagged substantial doubt about its ability to continue as a going concern due to high operating …

Why (ATRA) Price Action Is Critical for Tactical Trading

This article analyzes Atara Biotherapeutics Inc. (NASDAQ: ATRA) for tactical trading, highlighting a strong near and mid-term sentiment despite a weak long-term outlook. It identifies an exceptional 234.0:1 risk-reward setup targeting a 70.2% gain against 0.3% risk. The analysis also provides specific institutional trading …

Where Does Lee & Man Paper Manufacturing (SEHK:2314) Valuation Sit After Half Year Earnings?

Will AVLAYAH’s Launch And Cash Windfall Reshape Denali Therapeutics' (DNLI) Investment Narrative

DFTX Stock Rallies As Psychedelic Drug Delivers Positive Anxiety Trial Results — Retail Says DT120 Could ‘Disrupt The Market’

William Blair Maintains VistaGen Therapeutics(VTGN.US) With Hold Rating

William Blair has reiterated its Hold rating for VistaGen Therapeutics (VTGN.US). The report from the investment firm indicates their continued neutral stance on the company's stock.

Woodline Partners (SABS) discloses 5.46M-share beneficial stake in SAB Biotherapeutics

Woodline Partners LP has filed an amended Schedule 13G, disclosing a beneficial ownership of 5,455,355 shares, or 6.8%, of SAB Biotherapeutics, Inc. common stock. This stake includes common shares and shares issuable from Series B Preferred Stock underlying Enrollment and Data Release Warrants. The …

Form 8K Galectin Therapeutics Inc For: 14 August By Investing.com

TGTX Stock Hits Fresh 52-Week High – Here’s Why Retail Is Bullish Despite Q1 Earnings Miss

Quince Therapeutics Releases Q2 2026 Financial Results

Quince Therapeutics reported a net loss of $75.5 million and a loss per share of $12.31 for Q2 2026, despite significant improvement from the previous year. The biotechnology company, specializing in rare diseases, is navigating the capital-intensive development phase, with Wall Street analysts holding …

Quince Adds Inhaled Rapamycin Program for Pulmonary Diseases

Quince Therapeutics reported its Q2 2026 financial results, including a $75.5 million net loss and $116 million in cash and equivalents expected to fund operations through 2028. This quarter was transformational for the company due to the acquisition of Orphai Therapeutics, adding the lead …

Eventide Asset Management (OVID) discloses 6.3% ownership stake in Ovid Therapeutics

Eventide Asset Management, LLC, along with Finny Kuruvilla and Robin C. John, has disclosed a 6.3% ownership stake in Ovid Therapeutics Inc. as of June 30, 2026. This ownership, totaling 11,812,241 shares of common stock, is held through the Eventide Healthcare & Life Sciences …

Ikarian Capital discloses 9.0% Quince Therapeutics (QNCX) ownership in Schedule 13G

Ikarian Capital, LLC and Neil Shahrestani have reported a 9.0% beneficial ownership stake in Quince Therapeutics, Inc. (QNCX) through a Schedule 13G SEC filing. This includes 91,789 shares with shared voting and dispositive power, based on 1,017,063 shares outstanding as of July 29, 2026. …

Nektar Therapeutics (NKTR) Could Be 52% Undervalued After Q2 Earnings Surprise

Ikarian Capital (KZIA) discloses 575,778 Kazia Therapeutics ADSs under 4.9% cap

Pliant Therapeutics (PLRX) gains 8.9% institutional holder in ADAR1 Capital

Cyclerion Therapeutics (CYCN): ADAR1 Capital discloses 7.0% beneficial ownership

ADAR1 Capital Management, LLC and Daniel Schneeberger have reported beneficial ownership of 7.0% of Cyclerion Therapeutics, Inc. (CYCN) common stock, totaling 298,757 shares. This ownership is held by private investment funds managed by ADAR1, with both reporting persons exercising shared voting and dispositive power. …